Hyloris PHARMACEUTICALS

Reformulating the Future

KBC Securities Life Sciences Conference

9 September 2021

Forward-Looking Statements

This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings. This presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (whether inside or outside such person’s organization or firm) or published for any purpose or under any circumstances.

This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This presentation does not contain all the information that a prospective purchaser of securities of the Company may desire or require in deciding whether or not to purchase such securities nor does it constitute a due diligence review and should not be construed as such. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any person into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

This presentation includes market, economic and industry data, which were obtained by the Company from scientific journals, industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers. While the information has been accurately reproduced, and in as far as the Company is aware and is able to ascertain from such third-party information, no facts have been omitted which would render the reproduction of this third-party information inaccurate or misleading, the Company cannot guarantee its accuracy or completeness. Accordingly, you should not place reliance on any of the market, economic and industry data contained in this presentation.

This presentation includes statements that are, or may be deemed to be, “forward-looking statements” which are based on current expectations and projections about future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, these forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. A number of factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in the materials should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the materials. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual results or otherwise.

By attending and otherwise accessing this presentation you will be deemed to have read and understood the contents of this disclaimer. In making an investment decision, you must rely on your own assessment, examination, analysis and enquiry of the Company.

Hyloris PHARMACEUTICALS

15,000 drugs in development in 2018



60 new drugs hit the market in 2018

High Unmet Medical Needs

Hyloris PHARMACEUTICALS

Rethinking, Reinventing, Optimising Existing Medications

To improve overall therapy outcomes

REFORMULATING

Changing dose or mode of administration

REPURPOSING



New therapeutic uses

For the benefit of patients, physicians, payors

Hyloris PHARMACEUTICALS

Patented Value-Added Medicines: Pharma's Sweet Spot

To improve therapy outcomes



Hyloris PHARMACEUTICALS

Faster Innovation at Much Lower Costs and Risks

Discovery, pre-clinical development | **Clinical Development** | **Regulatory submission & decision**

15 YEARS ON AVERAGE
~1 BILLION COSTS ON AVERAGE

"Traditional Pharma-Biotech Model"

Feasibility, formulation, production | **Clinical Development** | **Regulatory submission & decision**

≤ 7 YEARS ON AVERAGE
≤ €7 MILLION COSTS ON AVERAGE*

"505(b)(2) value-added medicines"

Hyloris PHARMACEUTICALS

Wouters *et al*, Journal of the American Medical Association, 2020

* Hyloris budget – average 505(b)(2) value-added product R&D cost is €15M

Putting Healthcare Needs at the Centre of Therapy Design

UNMET MEDICAL NEEDS





Hyloris PHARMACEUTICALS

To Drive Continuous Growth and Create Shareholders' Value

Acquisition and in-licensing of product candidates based on

- Clear scientific and medical rationale based on physicians'input
- Approved, well-known molecules
- Clear regulatory pathway
- Landscape review & patent protection
- Addressable market need
- Added value to the healthcare system



Continuously growing diversified product portfolio characterised by

- Fast market adoption
- Maximized ROI
- Addressing clear unmet needs
- Large potential

Ambition to become a leader in value-added medicines

Hyloris PHARMACEUTICALS

Broad, Innovative Portfolio: Expand to ~30 Assets by 2024

Product	RoA	Indication	Formulation and Manufacturing	Clinical Development	Regulatory Filing	Expected Launch
CARDIOVASCULAR (CV) PORTFOLIO			**Maximum 7 years**			
Sotalol IV	IV	Atrial fibrillation	*Launched in U.S./partnered with AltaThera*			’20[1] ✓
Dofetilide IV	IV	Atrial fibrillation				’23
Metolazone IV	IV	Congestive heart failure				’24
HY-073	IV	Acute coronary syndrome				’25
HY-074	IV	Acute coronary syndrome				’25
HY-075	Oral Liquid	Coronary heart disease				’24
OTHER VALUE-ADDED PORTFOLIO			**Maximum 7 years**			
Maxigesic® IV	IV	Post-operative pain	*Licensed in >100 countries/partnered with AFT Pharmaceuticals*			‘20[2] ✓
TXA Acid RTU	IV	Excessive bleeding				’22
HY-038	IM	(Specific) deficiency				’23
HY-004	Oral Liquid	Specific dental indication				’24
Miconazole-DB	Topical	Severe and rVVC				TBD
Atomoxetine	Oral Liquid	ADHD				’23
HY-029	Oral Liquid	Viral infection				’24

[1] *Under the new expanded label*
[2] *Marketing application to the U.S. FDA currently being prepared*
Our two high barrier generic products, HY-016 and Fusidic Acid Cream have not been included

Intended to be commercialised by Hyloris
Intended to be commercialised with partner

Hyloris PHARMACEUTICALS

IV: intravenous ; RTU: ready to use; IM: intra-muscular

TXA: tranexamic; ADHD: attention deficit hyperactivity disorder; Miconazole-DB: miconazole-domiphen bromide ; rVVC: recurrent vulvovaginal candidiasis

High Unmet Needs in Atrial Fibrillation (AF)

Atrial Fibrillation: a life-threatening disease

- Characterised by an irregular and often abnormal high heart rate



AF mechanism[1]

- **Complications:** 5x higher risk of stroke[2], 3x higher risk of heart failure[3]
- Contributes to about **158,000 deaths** each year in the U.S.[4]
- **U.S prevalence** expected to double to **12M by 2030[4]**
- **454,000[4]** AF-related **hospitalisations** per year in the U.S.
- **Majority** of hospitalised patients **receives** an **antiarrhythmic drug**

Current treatments could be improved

- Blood thinners
- Heart rate medicines
- **Heart rhythm medicines**

LIMITATIONS

Rhythm control drugs have **life-threatening side effects**

FDA Oral sotalol carries black box warning



Incidence of *Torsade de Pointes (abnormal heart rhythm – a serious side effect)* is 0.5-5.8%[5] on oral sotalol (dose-related)

Need for safer and more effective treatments

Hyloris PHARMACEUTICALS

[1] Mayo Foundation for Medical Education and Research, 2016; [2]Leila et al, 2011, [3]Kotecha and Piccini, 2015, Atrial fibrillation in heart failure: what should we do?; [4] Centres for Disease Control and Prevention; [5] McGill Case 86, 2012, ECG

Sotalol IV Offers Benefits to Patients, Physicians and Payors

Commercial partner AltaThera expanded their sales force in 2021 to accelerate roll-out in the U.S.

ALTATHERA PHARMACEUTICALS

Fast onset, particularly crucial in acute AF settings

Oral sotalol initiation



Sotalol IV loading dose



Steady state blood level after in 1 day with Sotalol IV (vs. 2.5 days with oral)

Hospital stay monitoring significantly reduced



Significant cost reduction potential

AF incremental cost saving

Opportunity for premium pricing compared to the generic oral formulation

Hyloris PHARMACEUTICALS

AF: atrial fibrillation

Maxigesic® IV has Potential to Combat the Opioid Crisis

Maxigesic® IV: a novel combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion

Paracetamol
blocks the pain message at the source

Maxigesic
Double action
(in IV form)

Ibuprofen
blocks the pain transmission

Phase 3 study results: Faster onset & higher pain relief at each time point[1]



Phase 3 study results: Opioid rescue medication: less used & used later[2]



[1] E. Daniels et al., 2019, Clinical Therapeutics;
Paracetamol is known as Acetaminophen in the U.S.

[2] E. Daniels et al., 2018, Clinical Therapeutics; Hartley C. Atkinson et al., 2015, Clin Drug Investig
FDC: fixed dose combination of acetaminophen 975mg + ibuprofen 292.5mg, refers to Maxigesic tablets

Maxigesic IV: Significant Growth of Commercial Footprint

AFT pharmaceuticals + strong local distribution partners

Countries	4 August 2021	31 March 2020
Licensed	100+	80
Registered	24	3
Launched	5	-



2021 year-to-date achievements:

- Launches in Germany and Austria
- Expansion of license agreement in South America
- License agreement with Hikma in the U.S.
- Europe: expansion of existing license plus additional licenses
- Patents granted across multiple jurisdictions
- Submission of NDA to the FDA ongoing

Hyloris PHARMACEUTICALS

Powerful R&D Engine: Leveraging our Network of Partners



Note: bubble size indicates relative amount of Hyloris time and capital required to complete
* Hyloris' budget
API: active pharmaceutical ingredient

Flexible, Hybrid Earnings and Commercialisation Model

1. CARDIOVASCULAR FRANCHISE

- Lean speciality U.S. sales team targeting hospital-affiliated cardiologists
- Exploit existing regulatory package for certain product candidates to partner in other key geographies
- Already a presence in the U.S. with Sotalol IV, commercialised by our partner AltaThera

2. OTHER PORTFOLIO

- Out-licensing to commercial partners across various geographies
- Create ability to quickly monetise assets via upfront and milestone payments
- Retain a large minority, or a small majority of net sales realised by partners

Hyloris PHARMACEUTICALS

The cardiovascular franchise for self-commercialisation excludes Sotalol IV, which is commercialised by our partner AltaTera and HY-075, which is envisaged to be commercialised by a partner (targeting the large retail market)

Launch of Own IV Cardiovascular Portfolio in the U.S.

- Build the right commercial team and manufacturing capabilities
- Focus on specialist cardiologists employed by hospitals in key sales territories

P&T = Pharmacy & Therapeutics is a committee at a hospital or health insurance plan that decides whether drugs appear on that entity's drug formulary

Robust IP Portfolio: Extended Period of Exclusivity

- Broad portfolio: exclusivity through 2039 in key pharma markets across the globe
- Wide range of protection: dosages, formulations, indications, methods for preparing a composition, manufacturing methods
- Additional layer of protection: knowhow, technological innovation and in-licensing

Hyloris PHARMACEUTICALS

Financial Highlights: Period Ending 30 June 2021

(in € thousand)	HY 2021	HY 2020	% change
Revenue and other income	**1,145**	**102**	**1,023%**
Revenues	838	82	922%
Other income	307	20	1,435%
Operating expenses	**(9,016)**	**(3,626)**	**149%**
R&D	(1,560)	(1,172)	33%
G&A	(1,608)	(2,454)	(34%)
Other (one-off expenses)	(5,770)	--	NA
Net cash (burn)/inflow [i]	**(10,934)**	**66,578**	**NA**
Cash and cash equivalents	**53,465**	**66,783**	**(20%)**

[i] For the period 1 January to 30 June

Key Factors

- Revenues: growth mainly driven by Maxigesic IV recognised income from milestones
- Operating expenses: impacted by one-off expense related to unwinding of agreements with the Alter Pharma Group
- Cash burn:
  - HY21: impacted by one-off cash outflow related to unwinding of agreements with Alter Pharma Group
  - HY20: positively impacted by financing activities (convertible bonds and IPO)

Hyloris PHARMACEUTICALS

Core Assets: Anticipated Value Inflection Milestones in 2021

Clinical

✓ HY-004: start Phase 1

- Atomoxetine: start + results pivotal study
- HY-004: results Phase 1 and preparations pivotal study
- Miconazole-DB: start Phase 2 study
- Other assets: preparations to start pivotal studies

Regulatory

✓ Tranexamic Acid RTU: marketing application in U.S.

- Maxigesic IV: marketing application in U.S.
- Maxigesic IV: additional approvals in key markets

Commercial

✓ Partnership Purna Female Healthcare

✓ Maxigesic IV: distribution agreements in EU and S. America

✓ Maxigesic IV: agreement with Hikma in the U.S.

✓ Maxigesic IV further roll-out

- Sotalol IV U.S. roll-out
- Commercial partnership(s)
- Out-licensing agreement(s)

- Expand R&D pipeline with 3 new product candidates

Hyloris PHARMACEUTICALS

Potential Game Changer, Geared for Growth

MULTIPLE SHOTS ON GOAL

≤ 7 years to market

≤ €7 million average cost to market

Lower risk as we start from existing drugs

Innovative, patented, value-added drug candidates

COMMERCIAL PORTFOLIO

2 patented products with partners

Addressing unmet needs

Build **U.S. commercial** team

Relevant improvements for patients, physicians and the healthcare system

Ambition to become the reference in value-added medicines over the coming years

Hyloris PHARMACEUTICALS

Questions?

Hyloris PHARMACEUTICALS



investorrelations@hyloris.com

Addendum:

- Background Info Product Pipeline
- 505(b)(2) Landscape
- Shareholders and Corporate Info

Hyloris PHARMACEUTICALS

Sourcing Product Opportunities Via Multiple Channels



Hyloris PHARMACEUTICALS

Selected Case Studies

Hyloris PHARMACEUTICALS

Unmet Needs in Severe and rVVC



Vulvovaginal candidiasis (VVC)

- Infection caused by *Candida* sp. yeast
- Causes irritation, vaginal discharge and intense itchiness
- **Affects 50% of all women** during their life
- ~175M drug products sold/year

Current medicines have limitations



Local **Systemic**

Side effects – Not efficacious in rVVC

Severe and recurring VVC

- **10% of all women globally**
- No effective treatments: drug-resistant biofilm
- $14.4 Bn annual estimated economic burden

No innovation over the past few decades

Hyloris PHARMACEUTICALS

G. Pappas *et al.*, Clinical Infectious Diseases (2016); J.D. Sobel *et al.*, Expert Opinion on Pharmacotherapy (2018)
Janssen-Cilag Ltd is the marketing authorisation holder of Gyno-Daktarin

Miconazole-DB has Potential to Cure Severe and rVVC

WELL-KNOWN ANTIMYCOTIC
MICONAZOLE (MCZ)
Prevents growth of fungus

REPURPOSED MOLECULE
DOMIPHEN BROMIDE (DB)
Potentiator for fungicidal activity

DUAL FUNGICIDAL ACTIVITY

Domiphen-bromide: anti-septic; identified as a miconazole potentiator through drug screening of large *drug repurposing library*

LOCAL TOPICAL FORMULATION



Unique mode-of-action

PURNA PHARMA



Infection expressed in area under the curve after 4 days of treatment and 10 days of follow-up in function of different formulations



Intravaginal fungal burden in log colony forming units (cfu) per swab during different therapies expressed in days post-infection (DPI)

Domiphen Bromide significantly enhances Miconazole efficacy *in vivo*

Hyloris PHARMACEUTICALS

Benhamou R. I., *et al*, ACS Chemical Biology, 2017
** ROS = reactive oxygen species*

J. Tits., J *et al.*, Antimicrob Agents Chemother (2020) ; K. De Cremer *et al.*, Antimicrobial agents and chemotherapy (2015)

High Unmet Needs in Atrial Fibrillation (AF)

Atrial Fibrillation: a life-threatening disease

- Characterised by an irregular and often abnormal high heart rate



AF mechanism[1]

- **Complications:** 5x higher risk of stroke[2], 3x higher risk of heart failure[3]
- Contributes to about **158,000 deaths** each year in the U.S.[4]
- **U.S prevalence** expected to double to **12M by 2030[4]**
- **454,000[4]** AF-related **hospitalisations** per year in the U.S.
- **Majority** of hospitalised patients **receives** an **antiarrhythmic drug**

Current treatments could be improved

- Blood thinners
- Heart rate medicines
- **Heart rhythm medicines**

LIMITATIONS

Rhythm control drugs have **life-threatening side effects**

FDA Oral sotalol carries black box warning



Incidence of *Torsade de Pointes (abnormal heart rhythm – a serious side effect)* is 0.5-5.8%[5] on oral sotalol (dose-related)

Need for safer and more effective treatments

Hyloris PHARMACEUTICALS

[1] Mayo Foundation for Medical Education and Research, 2016; [2]Leila et al, 2011, [3]Kotecha and Piccini, 2015, Atrial fibrillation in heart failure: what should we do?; [4] Centres for Disease Control and Prevention; [5] McGill Case 86, 2012, ECG

Sotalol IV Offers Benefits to Patients, Physicians and Payors

Fast onset, particularly crucial in acute settings

Oral sotalol initiation



Sotalol IV loading dose



Steady state blood level after in 1 day with Sotalol IV (vs. 2.5 days with oral)

Hospital stay monitoring significantly reduced



Significant cost reduction potential

AF incremental cost saving

Opportunity for premium pricing compared to the generic oral formulation

Benefits for:

Hospitals *Payors*

Approval Sotalol IV New Label (label extension)

NEW SOTALOL IV™ sotalol hydrochloride injection

New Dosing Information

American Heart Association

March 2020: FDA approval label extension to include the **initiation of loading** on Sotalol IV in patients who are prescribed oral sotalol and for **dose escalation** for chronic administration of an increased dose of oral sotalol

Commercialisation in the U.S. by Hyloris' partner ALTATHERA PHARMACEUTICALS

Hyloris eligible to receive from its partner AltaThera:

- Increasing sales-related fees on net sales derived from Sotalol IV in the U.S.
- Five one-time sales-related milestone payments of increasing amounts, totalling maximum $18M
- First milestone to materialise when annual net sales are ≥ $20M

Hyloris PHARMACEUTICALS

[1] FDA; [2] Kathy Tang et al., 2018, Cost minimization analysis of Atrial Fibrillation and Atrial Flutter through intravenous Sotalol loading

Sotalol IV New Label, Strong Support From Medical Community



Sotalol IV under its new label has potential to take an important share in the antiarrhythmic market

Hyloris PHARMACEUTICALS

[1] AltaThera survey performed in the U.S., 2018; [2] Percentages for Sotalol IV indicate the share cardiologists think this product can capture of patients who are administered an arrhythmic drug; [3] The number of total persons surveyed (n) was 30

High Unmet Needs in Post-Operative Pain Management

Gap in moderately severe pain care space



Current treatment options are suboptimal



Market size breakdown

Maxigesic® platform expected to generate **peak sales of $442M** in U.S., Japan and EU5[1] (incl. Maxigesic® in oral form)[2]

Need for safer and more effective non-opioid treatment options

Hyloris entitled to a share on any revenues[3] generated by commercial partner AFT pharmaceuticals

Hyloris PHARMACEUTICALS

[1] EU5: France, Germany, Italy, Spain, UK; [2] AFT Pharmaceuticals & Delveinsight (Post-Operative Pain Market Insights, Epidemiology and Market Forecast—2028; Platform includes Maxigesic® in oral form); [3] Excluding Australia and New Zealand

Maxigesic® IV has Potential to Combat the Opioid Crisis

Maxigesic® IV: a novel combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion

Paracetamol
blocks the pain message at the source

Maxigesic
Double action
(in IV form)

Ibuprofen
blocks the pain transmission

Phase 3 study results: Faster onset & higher pain relief at each time point[1]



Phase 3 study results: Opioid rescue medication: less used & used later[2]



[1] E. Daniels et al., 2019, Clinical Therapeutics;
Paracetamol is known as Acetaminophen in the U.S.

[2] E. Daniels et al., 2018, Clinical Therapeutics; Hartley C. Atkinson et al., 2015, Clin Drug Investig
FDC: fixed dose combination of acetaminophen 975mg + ibuprofen 292.5mg, refers to Maxigesic tablets

Market Landscape Value-Added 505(b)(2) Medicines

Hyloris PHARMACEUTICALS

Increasing Use of 505(b)(2) Pathway in the Industry

505(b)(2) approvals (2003-2019)



Repurposed drugs have 150% higher change of success to reach the market compared to NCEs*

NDA approvals in 2019 by pathway



505(b)2 approvals ■ 505(b)1 approvals ■ Undetermined

505(b)(2) approvals by route of administration



Injection ■ Oral ■ Opthalmic ■ Topical ■ Nasal ■ Other

505(b)2 approvals by type



■ New formulation or manufacturer
■ New combination
■ New active ingredient
■ Already marketed
■ New dosage form
■ New molecular entity
■ Unknown

Hyloris PHARMACEUTICALS

Camargo Pharma 2020
* Thayer, Drug Repurposing, 2012

Average Peak Sales of Value-Added 505(b)(2) Products



https://www.pharmexec.com/view/505b2-pathway-competitiveness-through-innovation-specialty-and-generic-companies

Performance of Select Number of 505(b)(2) Products

	Product name	What changed in 505(b)(2)	Indication	Company	2019 Sales
REFORMULATED	Avycaz	New combination	Complicated intra-abdominal and urinary tract infections	Allergan (AbbVie)	$117M
	Belbuca	New dosage form	Chronic pain	BioDelivery Sciences	$98M
	Vasostrict	New dosage form	Hypotension in adults with vasodilatory shock	Endo	$531M
	Abraxane	New formulation	Metastatic breast cancer	Celgene (BMS)	$1,200M
	Restasis	New route of administration	Chronic dry eye syndrome	Allergan (AbbVie)	$1,188M
	Neoral	New formulation	Immunosuppressant to prevent organ rejection after kidney, heart or liver transplant	Sandoz (Novartis)	$419M
	Kaletra	New combination and formulation	HIV infections	Abbott (AbbVie)	$283M
REPURPOSED	Viagra	New indication	Erectile dysfunction	Pfizer	$2,000M[a]
	Thalomid	New indication	Multiple myeloma	Celgene (BMS)	$500M[b]
	Tecfidera	New indication	Multiple sclerosis	Biogen	$4,430M
	Revatio	New indication	Pulmonary arterial hypertension	Pfizer	$144M
	Propecia	New indication	Male pattern baldness	Merck	$447M[c]
	Rituxan	New indication	Rheumatoid arthritis	Biogen & Roche	$1,200M[d]

[a] Sales in 2012, prior to generic entrants
[b] Sales in 2008 prior introduction of Thalomid analogue drug Revlimid (Celgene)
[c] Sales in 2010, prior to generic entrants
[d] Sales in 2013, prior to biosimilar entrants

Hyloris PHARMACEUTICALS

Value-Added 505(b)(2) Landscape

Geographical spread of 505(b)(2) (tentative) approvals 2015-2018 (# 221)



Top-3 applicants 2015-2018:

Country	Company	# of 505(b)(2) approvals
	FRESENIUS KABI	12
	SUN PHARMA	7
	EXELA PHARMA SCIENCES	4

Select Listed Competitors:

Country	Company	# of 505(b)(2) approvals 2011 - 2019	Formulation route
	EAGLE PHARMACEUTICALS	3	IV (infusion)
	HERON THERAPEUTICS	2	Injection, injectable emulsion
	eTon PHARMACEUTICALS	1	RTU injectable
	PACIRA PHARMACEUTICALS, INC.	1	Injectable suspension
	ani Pharmaceuticals, Inc.	Acquired a portfolio of 505(b)(2) product candidates from Coeptis	

Hyloris PHARMACEUTICALS

Shareholders and Corporate Information

Hyloris PHARMACEUTICALS

Shareholders' Information

Major shareholders



Bank	Analyst	Rating
KBC Securities	Lenny Van Steenhuyse	Buy
Kempen	René Wouters	Buy
Berenberg	Beatrice Allen	Buy

Hyloris is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Hyloris' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Hyloris or its management

HY21 cash position	€53.47 million
Share capital (excluding share premium)	€129,163.16
Total number of outstanding voting rights (= denominator)	25,832,632
Total number of securities carrying voting rights not yet issued	1,908,000

Hyloris PHARMACEUTICALS

Founders with Impressive Track Record and Industry Expertise

2005

DOCPHARMA — **acquired for €218M** — *by* — Mylan Matrix

Founded by Leon & Stijn Van Rompay
Generics and Pharmacy Sales & Devices

2013

UTERON PHARMA — **acquired for up to $305M** — *by* — Watson / Allergan

Founded by Stijn Van Rompay & François Fornieri
Women's Health

2015

Uteron shareholders — **sold Estelle® for >€250M** — *to* — mithra PHARMACEUTICALS

2016

Novalon — **50% stake acquired for €9.4M** — *by* — mithra PHARMACEUTICALS

Co-founded by Stijn Van Rompay
Controlled Release Implants

2017

Alter Pharma — **partially acquired** — *by* — Riverside

Founded by Stijn Van Rompay & Thomas Jacobsen
Generics and Pharmacy Sales Products

Combined transactions created additional shareholder value of >€550 million

Hyloris PHARMACEUTICALS

Executive Management Team

- In-depth knowledge of regulatory affairs, market access and the capital markets; involved in > 80 approved drugs, executed >250 licensing transactions; established track record of shareholder value creation
- Hyloris currently employs 23 people, 7 nationalities

Stijn Van Rompay - Chief Executive Officer

- >20 years of experience in leadership positions in pharma
- Co-founded, managed, and exited multiple pharma companies

Alter Pharma · Actavis · UTERON PHARMA · Mylan · DOCPHARMA

Thomas Jacobsen - Chief Business Development Officer

- >20 years of experience in pharma
- Expertise in operational management, and business & product development

DOCPHARMA · Mylan · Alter Pharma · Alternova

Dietmar Aichhorn - Chief Operating Officer

- >20 years of experience in various scientific roles in pharma
- Expert in technical and clinical development and regulatory affairs in the U.S., EU and other key geographies

Mylan · SANDOZ · polpharma · ViraTherapeutics

Chief Financial Officer

Active search ongoing

Koenraad Van der Elst - Chief Legal Officer

- >30 years of experience as external and in-house legal and general counsel at various listed companies
- Involved in numerous capital and M&A transactions worldwide

Nikon · PUNCH · Koramic

Hyloris PHARMACEUTICALS

Board of Directors

Stefan Yee
Chairman, Non-Executive Director

PE Group · unifiedpost · DOCPHARMA · UTERON · KPMG

Marc Foidart[4]
Independent Director

noshaq · Épimède · EyeD Pharma

Stijn Van Rompay[1]
Chief Executive Officer, Executive Director

DOCPHARMA · UTERON · Alter Pharma · Actavis · Mylan

Carolyn Myers
Independent Director

Bioensemble Ltd. · Allergan · Forest Laboratories, Inc.

Thomas Jacobsen[2]
Chief Business Development Officer, Executive Director

DOCPHARMA · Mylan · Alter Pharma · Alternova

James Gale
Independent Director

SIGNET · Alpex Pharma · Knight · GRUNTAL & Co

Leon Van Rompay[3]
Non-Executive Director

DOCPHARMA · UTERON · Belgian Pharmaceutical Industry Association · Zambon

Chris Buyse[5]
Independent Director

ThromboGenics · cropdesign · KEYWARE TECHNOLOGIES

Hyloris PHARMACEUTICALS

[1] Acting through SVR Management BV; [2] Acting through Jacobsen Management BV; [3] Acting through Van Rompay Management BV; [4] Acting through Noshaq Partners SCRL; [5] Nominated for approval at the AGM on 8 June 2021 - Acting through Pienter Jan BV